Literature DB >> 1778851

Role of OmpD2 and chromosomal beta-lactamase in carbapenem resistance in clinical isolates of Pseudomonas aeruginosa.

S Satake1, H Yoneyama, T Nakae.   

Abstract

Imipenem-resistant clinical isolates of Pseudomonas aeruginosa were divided into two categories: (i) isolates that were moderately resistant to imipenem (MIC 6.25 mg/L) that produced trace amounts of protein D2 detected with immunoblotting using anti-protein D2 antibody, but not when stained with Coomassie blue and had inducible class 1 beta-lactamase expression; (ii) isolates that were highly resistant to several beta-lactams, including meropenem, with no protein D2 by staining or immunoblotting and had stably derepressed beta-lactamase. Laboratory strains were isolated and analyzed: (i) mutants lacking protein D2, or (ii) lacking protein D2 and producing stably derepressed beta-lactamase with carbapenem resistance similar to the clinical isolates. (iii) mutants producing undetectable beta-lactamase which were four-fold more susceptible to imipenem than the mutant producing stably derepressed beta-lactamase or the strain with inducible beta-lactamase. These data suggests that beta-lactamase and outer membrane permeability govern meropenem-resistance in P. aeruginosa.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1778851     DOI: 10.1093/jac/28.2.199

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  16 in total

1.  Resistance to beta-lactam antibiotics in Pseudomonas aeruginosa due to interplay between the MexAB-OprM efflux pump and beta-lactamase.

Authors:  T Nakae; A Nakajima; T Ono; K Saito; H Yoneyama
Journal:  Antimicrob Agents Chemother       Date:  1999-05       Impact factor: 5.191

2.  Nucleotide sequence of the protein D2 gene of Pseudomonas aeruginosa.

Authors:  H Yoneyama; E Yoshihara; T Nakae
Journal:  Antimicrob Agents Chemother       Date:  1992-08       Impact factor: 5.191

3.  Lack of additive effect between mechanisms of resistance to carbapenems and other beta-lactam agents in Pseudomonas aeruginosa.

Authors:  C Dib; J Trias; V Jarlier
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-11       Impact factor: 3.267

4.  Emergence of resistance to beta-lactam agents in Pseudomonas aeruginosa with group I beta-lactamases in Spain.

Authors:  K Colom; A Fdz-Aranguiz; E Suinaga; R Cisterna
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1995-11       Impact factor: 3.267

5.  Imipenem and meropenem: Comparison of in vitro activity, pharmacokinetics, clinical trials and adverse effects.

Authors:  G G Zhanel; A E Simor; L Vercaigne; L Mandell
Journal:  Can J Infect Dis       Date:  1998-07

6.  Role of cephalosporinase in carbapenem resistance of clinical isolates of Pseudomonas aeruginosa.

Authors:  X Y Zhou; M D Kitzis; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1993-06       Impact factor: 5.191

Review 7.  Non-canonical mechanisms of antibiotic resistance.

Authors:  J L Martínez; J Blázquez; F Baquero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-12       Impact factor: 3.267

8.  Relationship between outer membrane protein profiles and resistance to ceftazidime, imipenem, and ciprofloxacin in Pseudomonas aeruginosa isolates from bacteremic patients.

Authors:  C Gimeno; D Navarro; F Savall; E Millás; M A Farga; J Garau; R Cisterna; J García-de-Lomas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-01       Impact factor: 3.267

9.  Activity of carbapenem BMS-181139 against Pseudomonas aeruginosa is not dependent on porin protein D2.

Authors:  J C Fung-Tomc; E Gradelski; B Kolek; B Minassian; M Pucci; R E Kessler; D P Bonner
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191

10.  Imipenem-resistant Pseudomonas aeruginosa: risk factors for nosocomial infections.

Authors:  Pinar Onguru; Ayse Erbay; Hurrem Bodur; Gulseren Baran; Esragul Akinci; Neriman Balaban; Mustafa Aydin Cevik
Journal:  J Korean Med Sci       Date:  2008-12-24       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.